-
News
New Funding by AMED for a Clinical Trial of GAIA-102 to Treat Malignant Ascites
-
News
GAIA BioMedicine Raised a Total of JPY 650 Million in Series A Round.
-
News
Our President & CEO Kazu Kuramori was at the Innate Killer Summit 2019 – Title:GAIA-102 as an NK Cell-Based “Upward Compatible” Modality Over CAR-T-Cell Therapy –
-
News
GAIA BioMedicine has released an experimental kit to produce highly activated NK-like cells for research use
News
![](/wp/wp-content/themes/gaia/common/images/page_bg_01.png)
![](/wp/wp-content/themes/gaia/common/images/page_bg_02.png)
![](/wp/wp-content/themes/gaia/common/images/page_bg_03.png)
![](/wp/wp-content/themes/gaia/common/images/page_bg_04.png)
![](/wp/wp-content/themes/gaia/common/images/page_bg_05.png)
![](/wp/wp-content/themes/gaia/common/images/page_bg_06.png)